PARP inhibitors in metastatic prostate cancer

Poly-ADP ribose polymerase inhibitors (PARPi) are an emerging therapeutic option for the treatment of prostate cancer. Their primary mechanism of action is via induction of synthetic lethality in cells with underlying deficiencies in homologous recombination repair (HRR). In men with metastatic cast...

Descripción completa

Detalles Bibliográficos
Autores principales: Taylor, Amy K., Kosoff, David, Emamekhoo, Hamid, Lang, Joshua M., Kyriakopoulos, Christos E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10165068/
https://www.ncbi.nlm.nih.gov/pubmed/37168382
http://dx.doi.org/10.3389/fonc.2023.1159557

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10165068/
https://www.ncbi.nlm.nih.gov/pubmed/37168382
http://dx.doi.org/10.3389/fonc.2023.1159557

Ejemplares similares